MedTrace Logo

Vestibular Versus Sublingual Route of AIT Tablets

NCT05119751 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 172

Last updated 2022-06-02

No results posted yet for this study

Summary

To evaluate the tolerability of the vestibular administration route of birch pollen, grass pollen, ragweed pollen, and house dust mite (HDM) AIT tablets compared with the sublingual route in adult subjects with allergic rhinitis/conjunctivitis (AR/C)

Conditions

Interventions

DRUG

tree 12 SQ-Bet

DAILY DOSE OF AIT TABLET

DRUG

GRASS 2800 BAU

DAILY DOSE OF AIT TABLET

DRUG

RAGWEED 12 AMB A 1-U

DAILY DOSE OF AIT TABLET

DRUG

HDM 12 SQ-HDM

DAILY DOSE OF AIT TABLET

Sponsors & Collaborators

  • ALK-Abelló A/S

    collaborator INDUSTRY

  • Clinique Spécialisée en Allergies de la Capitale

    lead OTHER

Principal Investigators

  • Remi Gagnon, MD · Clinique Spécialisée en Allergies de la Capitale

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-25
Primary Completion
2022-04-05
Completion
2022-04-21

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05119751 on ClinicalTrials.gov